AMP Increases Position in ANTH and Cuts Position in CYTR in Hypo Fund


Last week AMP trimmed half of its position in CYTR by selling 27,802 shares at a value of $0.83/share. The transaction totaled ~$23K. These positions were up 97.7% from the initial investment with a total gain of ~$11.5K.

AMP started an initial position in CYTR back in October 2016 and eventually built up a position of more than $37K by January 2017. Since then we have gradually trimmed down our position in the company.

As well as selling shares in CYTR, AMP increased its position in Anthera Pharmaceuticals. AMP invested an additional $12.5K at a share price of $1.28/share. AMP now owns $50K of ANTH in its hypothetical fund.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon